Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Dr Reddy’s Q3 Preview | Revenue expected to increase 10-15%, PAT likely to grow 22-25%

ICICI Securities expects the India business to grow 10 percent YoY and that in the US by 12.8 percent QoQ led by new launches. It also foresees Russia, CIS & ROW (Rest of World) to show steady growth

January 28, 2022 / 12:29 PM IST
Representative image

Representative image

  • bselive
  • nselive
Todays L/H

Dr Reddy’s Laboratories, one of India’s top drugmakers with strong overseas play, is expected to report a healthy year-on-year growth in the domestic formulations business when it reports its third-quarter results on January 28.

Strong traction in chronic therapies and the addition of sales from Wockhardt’s portfolio would drive the growth, experts said. The Hyderabad-based firm’s main markets of the US and Canada are also expected to grow in the mid-teens.

The company is expected to report a consolidated net profit of Rs 780–780 crore for the quarter, up 22-25 percent from the year-ago period. On a sequential basis, the net profit is expected to decline 18-22 percent.

Brokerages expect the company to report a 10-15 percent year-on-year growth in consolidated revenue for the quarter at Rs 5,400–5,600 crore. On a sequential basis, the revenues may slip 3–6 percent.